Extract

Naxitamab-gqgk is a glycolipid disialoganglioside (GD2)-binding monoclonal antibody antineoplastic agent.

Class: 10:00 • Antineoplastic Agents (AHFS primary) Brands: Danyelza®

...

Uses

Naxitamab-gqgk has the following uses:

...

Dosage and Administration

General.

Naxitamab-gqgk is available in the following dosage form(s) and strength(s): Concentrate for injection: 40 mg/10 mL (4 mg/mL) in a single-dose vial.

Dosage.

It is  essential  that the manufacturer’s labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

Pediatric Patients.

Dosage and Administration.

The recommended dosage of naxitamab-gqgk is 3 mg/kg/day (up to 150 mg/day), administered as an intravenous infusion after dilution on days 1, 3, and 5 of each treatment cycle. Treatment cycles are repeated every 4 weeks until complete response or partial response, followed by 5 additional cycles every 4 weeks. Subsequent cycles may be repeated every 8 weeks.

Administer pre-infusion medications and supportive treatment, as appropriate, during infusion.

You do not currently have access to this article.

Comments

0 Comments
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.